Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XBD173 in generalized anxiety disorder
NCT00108836Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2005
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of emapunil in generalized anxiety disorder (GAD), sponsored by Novartis. Started Mar 2005; status: completed.
02
Drugs
emapunil
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT00108836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00108836.